Hadas Reuveni

Dr. Hadas Reuveni has served as Purple Biotech's Vice President Research and Development since 2017. Prior to joining Purple, she co-invented the technology of TyrNovo, a biotech startup company. Dr. Reuveni has been engaged with the scientific projects in TyrNovo's portfolio since 2005, and has nearly two decades of research and development experience in biotechnology. Dr. Reuveni founded and served as CEO of TyrNovo's predecessor, NovoTyr, which developed small molecules for the treatment of cancer and neurodegenerative diseases. She also founded and served as a Director and Chief Science Officer of AngioB, a startup that developed GPCR-based agents for multiple indications, from 2006 to 2010. Prior to that, she was the Director of Research & Development at Keryx Biopharmaceuticals (NASDAQ: KRX) from 2001 to 2004. Dr. Reuveni also served as a scientific consultant for Integra Holdings, Campus Bio Management, and BioLineRX (NASDAQ/TASE: BLRX). Dr. Reuveni received her PhD from The Hebrew University of Jerusalem.